Press Releases

Date Title and Summary Additional Formats  
Toggle Summary Karyopharm Therapeutics Announces Award of Grant From National Multiple Sclerosis Society to Further Develop Selective Inhibitors of Nuclear Export (SINE) Compounds
NATICK, Mass., Jan. 8, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases,
View HTML
Toggle Summary Karyopharm Therapeutics Added to Russell 3000(R) and Russell 2000(R) Indexes
NATICK, Mass., Dec. 20, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major
View HTML
Toggle Summary Karyopharm Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares in Its Initial Public Offering
NATICK, Mass., Dec. 11, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major
View HTML
Toggle Summary Karyopharm Therapeutics Presents Promising Data for Selinexor, an Oral, First-in-Class Selective Inhibitors of Nuclear Export (SINE) Compound, in Hematologic Malignancies at 2013 ASH Annual Meeting
NATICK, Mass., Dec. 8, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases,
View HTML
Toggle Summary Karyopharm Therapeutics Announces Highlights From Poster Presentations on Selective Inhibitors of Nuclear Export (SINE) Compounds in Hematologic Malignancies at 2013 ASH Annual Meeting
NATICK, Mass., Dec. 7, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases,
View HTML
Toggle Summary Karyopharm Therapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference
NATICK, Mass., Dec. 5, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases,
View HTML
Toggle Summary Karyopharm Therapeutics to Host Investor Reception and Webcast at the 2013 American Society of Hematology Annual Meeting
NATICK, Mass., Dec. 2, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases,
View HTML
Toggle Summary Karyopharm Therapeutics Announces Data Presentations at American Society of Hematology Annual Meeting
NATICK, Mass. , Nov. 8, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases,
View HTML
Toggle Summary Karyopharm Therapeutics Announces Pricing of Initial Public Offering
Karyopharm Therapeutics Announces Pricing of Initial Public Offering NATICK, Mass., Nov. 5, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing novel first-in-class drugs directed against nuclear transport targets for the treatment of
View HTML
Toggle Summary Karyopharm Therapeutics Announces Oral Presentations at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) XPO1 Antagonists in preclinical models of Autoimmune Disease
Karyopharm Therapeutics Announces Oral Presentations at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) XPO1 Antagonists in preclinical models of Autoimmune Disease Natick, Mass . – October 22, 2013 – Karyopharm Therapeutics Inc.
View HTML